<DOC>
	<DOCNO>NCT01193608</DOCNO>
	<brief_summary>This study evaluate safety multiple dose AAB-003 ( PF-05236812 ) patient mild moderate Alzheimer 's Disease . Patients receive either AAB-003 ( PF-05236812 ) placebo . Each patient 's participation last approximately 41 week .</brief_summary>
	<brief_title>Study Evaluating The Safety Of AAB-003 ( PF-05236812 ) In Subjects With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable Alzheimer 's Disease MMSE score 1626 , brain MRI consistent diagnosis Alzheimer 's Disease Concurrent use cholinesterase inhibitor memantine allow , stable . Caregiver participate able attend clinic visit patient Significant neurological disease Alzheimer 's Disease Major psychiatric disorder Contraindication undergo brain MRI ( e.g. , pacemaker , CSF shunt , foreign metal object body ) Women childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Safety Study</keyword>
	<keyword>Adaptive</keyword>
	<keyword>Double Blind</keyword>
</DOC>